.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HIPARCO randomized trial examined the effect of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea and resistant hypertension. Adults receiving multiple antihypertensive drugs were randomized to CPAP or no CPAP while continuing their usual medical treatment. After follow-up, CPAP produced a modest but clinically relevant improvement in 24-hour blood pressure measures and increased the proportion of patients who achieved a better nocturnal blood pressure pattern. The study reinforces an important clinical screening message: obstructive sleep apnea should be considered in patients whose hypertension remains difficult to control, even when classic symptoms such as loud snoring are not the presenting complaint. For respiratory physicians, the value of the paper is also multidisciplinary. OSA treatment is not only about sleepiness and sleep quality; it can contribute to cardiovascular risk management. The findings support the conference session emphasis on screening triggers beyond snoring, including resistant hypertension and metabolic disease, and they show why sleep assessment can be clinically meaningful across internal medicine and pulmonary practice.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HIPARCO randomized trial examined the effect of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea and resistant hypertension. Adults receiving multiple antihypertensive drugs were randomized to CPAP or no CPAP while continuing their usual medical treatment. After follow-up, CPAP produced a modest but clinically relevant improvement in 24-hour blood pressure measures and increased the proportion of patients who achieved a better nocturnal blood pressure pattern. The study reinforces an important clinical screening message: obstructive sleep apnea should be considered in patients whose hypertension remains difficult to control, even when classic symptoms such as loud snoring are not the presenting complaint. For respiratory physicians, the value of the paper is also multidisciplinary. OSA treatment is not only about sleepiness and sleep quality; it can contribute to cardiovascular risk management. The findings support the conference session emphasis on screening triggers beyond snoring, including resistant hypertension and metabolic disease, and they show why sleep assessment can be clinically meaningful across internal medicine and pulmonary practice.
4 weeks back
Explore the therapeutic promise of TLR7 and TLR8 inhibitors in managing systemic lupus erythematosus and monogenic autoimmune diseases. Learn how targeting endolysosomal single-stranded RNA sensing and regulatory checkpoints like UNC93B1 and PLD4 offers precision treatment without broad immunosuppression.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Yesterday
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Yesterday
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Yesterday
